Search

Your search keyword '"Schönland, Stefan"' showing total 496 results
Start Over Author "Schönland, Stefan" Publication Type Academic Journals
496 results on '"Schönland, Stefan"'

2. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

Author

Lübke, Johannes, Christen, Deborah, Schwaab, Juliana, Kaiser, Anne, Naumann, Nicole, Shoumariyeh, Khalid, Jentzsch, Madlen, Sockel, Katja, Schaffrath, Judith, Ayuk, Francis A., Stelljes, Matthias, Hilgendorf, Inken, Sala, Elisa, Kaivers, Jennifer, Schönland, Stefan, Wittke, Christoph, Hertenstein, Bernd, Radsak, Markus, Kaiser, Ulrich, Brückl, Valeska, Kröger, Nicolaus, Brümmendorf, Tim H., Hofmann, Wolf-Karsten, Klein, Stefan, Jost, Edgar, Reiter, Andreas, and Panse, Jens

Published
2024
Full Text
View/download PDF

3. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Author

Beksac, Meral, Eikema, Diderik-Jan, Koster, Linda, Hulin, Cyrille, Poiré, Xavier, Hamladji, Rose-Marie, Gromek, Tomasz, Bazarbachi, Ali, Ozkurt, Zubeyde Nur, Pabst, Thomas, Ben Othman, Tarek, Finke, Jürgen, Pirogova, Olga, Wu, Depei, Hayat, Amjad, Hilgendorf, Inken, Tholouli, Eleni, de Wreede, Liesbeth C., Schönland, Stefan, Garderet, Laurent, Drozd-Sokolowska, Joanna, Raj, Kavita, Hayden, Patrick J., Yakoub-Agha, Ibrahim, and McLornan, Donal P.

Published
2024
Full Text
View/download PDF

5. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

Author

Köhrer, Sebastian, Dittrich, Tobias, Schorb, Martin, Weinhold, Niels, Haberbosch, Isabella, Börmel, Mandy, Pajor, Gabor, Goldschmidt, Hartmut, Müller-Tidow, Carsten, Raab, Marc S., John, Lukas, Seckinger, Anja, Brobeil, Alexander, Dreger, Peter, Tornóczky, Tamás, Pajor, László, Hegenbart, Ute, Schönland, Stefan O., Schwab, Yannick, and Krämer, Alwin

Published
2023
Full Text
View/download PDF

6. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

Author

Tilmont, Rémi, Yakoub-Agha, Ibrahim, Eikema, Diderik-Jan, Zinger, Nienke, Haenel, Mathias, Schaap, Nicolaas, Arroyo, Concepcion Herrera, Schuermans, Christine, Besemer, Britta, Engelhardt, Monika, Kuball, Jürgen, Michieli, Mariagrazia, Schub, Natalie, Wilson, Keith M. O., Bourhis, Jean Henri, Mateos, Maria Victoria, Rabin, Neil, Jost, Edgar, Kröger, Nicolaus, Moraleda, José M, Za, Tommaso, Hayden, Patrick J., Beksac, Meral, Mclornan, Donal, Schönland, Stefan, and Manier, Salomon

Published
2023
Full Text
View/download PDF

8. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

Author

Beksac, Meral, Iacobelli, Simona, Koster, Linda, Cornelissen, Jan, Griskevicius, Laimonas, Rabin, Neil K., Stoppa, Anne Marie, Meijer, Ellen, Mear, Jean-Baptiste, Zeerleder, Sacha, Mayer, Jiri, Fenk, Roland, Fegueux, Nathalie, Chevallier, Patrice, Konirova, Eva, Snowden, John A., Engelhardt, Monika, Orchard, Kim, Hulin, Cyrille, Schaap, Nicolaas, Sossa, Claudia, Elmaagacli, Ahmet, McLornan, Donal P., Hayden, Patrick J., Schönland, Stefan, and Yakoub-Agha, Ibrahim

Published
2023
Full Text
View/download PDF

9. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

Author

Jaccard, Arnaud, Bridoux, Frank, Roeloffzen, Wilfried, Minnema, Monique C., Bergantim, Rui, Hájek, Roman, João, Cristina, Cibeira, M. Teresa, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Dimopoulos, Meletios A., Ravichandran, Sriram, Hegenbart, Ute, Agis, Hermine, Gros, Blanca, Asra, Aisha, Magarotto, Valeria, Cheliotis, Giorgos, Psarros, Giorgos, Sonneveld, Pieter, Wechalekar, Ashutosh, and Kastritis, Efstathios

Published
2024
Full Text
View/download PDF

12. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Author

Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Jaccard, Arnaud, Bridoux, Frank, Dimopoulos, Meletios A., Ravichandran, Sriram, Hegenbart, Ute, Roeloffzen, Wilfried, Cibeira, M. Teresa, Agis, Hermine, Minnema, Monique C., Bergantim, Rui, Hájek, Roman, João, Cristina, Leonidakis, Alexandros, Cheliotis, Giorgos, Sonneveld, Pieter, Kastritis, Efstathios, and Wechalekar, Ashutosh

Published
2023
Full Text
View/download PDF

13. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT

Author

Waszczuk-Gajda, Anna, Gras, Luuk, de Wreede, Liesbeth C., Sirait, Tiarlan, Illes, Arpad, Ozkurt, Zubeyde Nur, Snowden, John A., Arat, Mutlu, Bulabois, Claude Eric, Niederland, Judith, Sever, Matjaz, Paneesha, Shankara, Potter, Victoria, Gadisseur, Alain, Chalopin, Thomas, Van Gorkom, Gwendolyn, López, Joaquin Martínez, Kerre, Tessa, Drozd-Sokolowska, Joanna, Raj, Kavita, Hayden, Patrick J., Beksac, Meral, Yakoub-Agha, Ibrahim, McLornan, Donal P., and Schönland, Stefan

Published
2023
Full Text
View/download PDF

14. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Author

Gertz, Morie A., Cohen, Adam D., Comenzo, Raymond L., Kastritis, Efstathios, Landau, Heather J., Libby, Edward N., Liedtke, Michaela, Sanchorawala, Vaishali, Schönland, Stefan, Wechalekar, Ashutosh, Zonder, Jeffrey A., Palladini, Giovanni, Walling, Jackie, Guthrie, Spencer, Nie, Christie, Karp, Carol, Jin, Yuying, Kinney, Gene G., and Merlini, Giampaolo

Published
2023
Full Text
View/download PDF

15. Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

Author

Beksac, Meral, Iacobelli, Simona, Koster, Linda, Cornelissen, Jan, Griskevicius, Laimonas, Rabin, Neil K., Stoppa, Anne Marie, Meijer, Ellen, Mear, Jean-Baptiste, Zeerleder, Sacha, Mayer, Jiri, Fenk, Roland, Fegueux, Nathalie, Chevallier, Patrice, Konirova, Eva, Snowden, John A., Engelhardt, Monika, Orchard, Kim, Hulin, Cyrille, Schaap, Nicolaas, Sossa, Claudia, Elmaagacli, Ahmet, McLornan, Donal P., Hayden, Patrick J., Schönland, Stefan, and Yakoub-Agha, Ibrahim

Published
2023
Full Text
View/download PDF

16. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT

Author

Machowicz, Rafal, Suarez, Felipe, Wiktor-Jedrzejczak, Wieslaw, Eikema, Diderik-Jan, de Wreede, Liesbeth C., Blok, Henric-Jan, Isaksson, Cecilia, Einsele, Hermann, Poiré, Xavier, van Dorp, Suzanne, Nikolousis, Emmanouil, Johansson, Jan-Erik, Kobbe, Guido, Zecca, Marco, Arnold, Renate, Gerbitz, Armin, Finke, Jürgen, Díez-Martín, Jose Luis, Bonifazi, Francesca, McQuaker, Grant, Lenhoff, Stig, Rohrlich, Pierre-Simon, Theobald, Matthias, Ljungman, Per, Collin, Matthew, Albert, Michael H., Ehninger, Gerhard, Carlson, Kristina, Halaburda, Kazimierz, Lehmberg, Kai, Schönland, Stefan, Yakoub-Agha, Ibrahim, Gennery, Andrew R., Lankester, Arjan C., and Kröger, Nicolaus

Published
2022
Full Text
View/download PDF

17. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

Author

Drozd-Sokołowska, Joanna, Gras, Luuk, Zinger, Nienke, Snowden, John A., Arat, Mutlu, Basak, Grzegorz, Pouli, Anastasia, Crawley, Charles, Wilson, Keith M. O., Tilly, Herve, Byrne, Jennifer, Bulabois, Claude Eric, Passweg, Jakob, Ozkurt, Zubeyde Nur, Schroyens, Wilfried, Lioure, Bruno, Colorado Araujo, Mercedes, Poiré, Xavier, Van Gorkom, Gwendolyn, Gurman, Gunhan, de Wreede, Liesbeth C., Hayden, Patrick J., Beksac, Meral, Schönland, Stefan O., and Yakoub-Agha, Ibrahim

Published
2022
Full Text
View/download PDF

18. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia

Author

Beelen, Dietrich W., Arnold, Renate, Stelljes, Matthias, Alakel, Nael, Brecht, Arne, Bug, Gesine, Bunjes, Donald, Faul, Christoph, Finke, Jürgen, Franke, Georg-Nikolaus, Holler, Ernst, Kobbe, Guido, Kröger, Nicolaus, Rösler, Wolf, Scheid, Christof, Schönland, Stefan, Stadler, Michael, Tischer, Johanna, Wagner-Drouet, Eva, Wendelin, Knut, Brüggemann, Monika, Reiser, Lena, Hoelzer, Dieter, and Gökbuget, Nicola

Published
2022
Full Text
View/download PDF

22. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.

Author

aus dem Siepen, Fabian, Meissner, Christopher, Hofmann, Eva, Hein, Selina, Nagel, Christian, Hegenbart, Ute, Schönland, Stefan O., Andre, Florian, Frey, Norbert, and Kristen, Arnt V.

Subjects
BRAIN natriuretic factor, SURVIVAL rate, KARNOFSKY Performance Status, VENTRICULAR ejection fraction, GLOMERULAR filtration rate, CARDIAC amyloidosis, HEART failure
Abstract

Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease that causes heart failure due to amyloid fibril deposition. Tafamidis was approved as the first causal treatment in 2020. We here report on real-world data in patients treated with tafamidis for at least 12 months according to the recently defined European Society for Cardiology (ESC) consensus criteria for disease progression. Methods and results: Three hundred and eight wildtype and 31 hereditary ATTR-CM patients were prospectively enrolled after first diagnosis of ATTR-CM and initiation of tafamidis 61 mg once daily treatment. After 12 months, significant deterioration in Karnofsky Index, estimated glomerular filtration rate (eGFR), N-terminal brain natriuretic peptide (NT-proBNP), septum thickness and left ventricular ejection fraction (LVEF) could be observed, significant disease progression was only detected in 25 patients (9%) using ESC consensus criteria. Mean survival time was 37 months with no differences between responders and non-responders. NT-proBNP was the only independent predictor for poor therapy response (p =.008). Conclusions: The majority of patients showed no significant disease progression according to the ESC consensus criteria after 12 months of therapy with tafamidis. However, at 12 months, treatment response based on the ESC consensus criteria was not associated with improved survival. Moreover, higher levels of NT-proBNP at diagnosis of ATTR-CM appears to predict poorer treatment response, confirming that timely initiation of therapy is advantageous. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Author

Hayden, Patrick J., Eikema, Dirk-Jan, de Wreede, Liesbeth C., Koster, Linda, Kröger, Nicolaus, Einsele, Hermann, Minnema, Monique, Dominietto, Alida, Potter, Michael, Passweg, Jacob, Bermúdez, Arancha, Nguyen-quoc, Stephanie, Platzbecker, Uwe, Tischer, Johanna, Ciceri, Fabio, Veelken, Joan Hendrik, Ljungman, Per, Schaap, Nicolaas, Forcade, Edouard, Carella, Angelo Michele, Gandemer, Virginie, Arcese, William, Bloor, Adrian, Olivieri, Attilio, Vincent, Laure, Beksac, Meral, Schönland, Stefan, and Yakoub-Agha, Ibrahim

Published
2021
Full Text
View/download PDF

25. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

Author

Havasi, Andrea, Heybeli, Cihan, Leung, Nelson, Angel-Korman, Avital, Sanchorawala, Vaishali, Cohen, Oliver, Wechalekar, Ashutosh, Bridoux, Frank, Jaffer, Insara, Gutgarts, Victoria, Hassoun, Hani, Levinson, Maya, Rosenbaum, Cara, Milani, Paolo, Palladini, Giovanni, Merlini, Giampaolo, Hegenbart, Ute, Schönland, Stefan, Veelken, Kaya, Pogrebinsky, Alexander, Doros, Gheorghe, and Landau, Heather

Published
2022
Full Text
View/download PDF

26. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Author

Vincent, Laure, Gras, Luuk, Ceballos, Patrice, Finke, Jürgen, Passweg, Jakob, Harel, Stéphanie, Rosinol, Laura, Minnema, Monique, Teipel, Raphael, van Doesum, Jaap, Hänel, Mathias, Lenain, Pascal, Botella-Garcia, Carmen, Koenecke, Christian, Ducastelle, Sophie, Sanz, Jaime, Schroyens, Wilfried, Zuckerman, Tsila, Monaco, Federico, Koster, Linda, de Wreede, Liesbeth, Hayden, Patrick J., Schönland, Stefan, Yakoub-Agha, Ibrahim, and Beksac, Meral

Published
2022
Full Text
View/download PDF

27. Search for AL amyloidosis risk factors using Mendelian randomization

Author

Saunders, Charlie N., Chattopadhyay, Subhayan, Huhn, Stefanie, Weinhold, Niels, Hoffmann, Per, Nöthen, Markus M., Jöckel, Karl-Heinz, Schmidt, Börge, Landi, Stefano, Goldschmidt, Hartmut, Milani, Paolo, Merlini, Giampaolo, Rowcieno, Dorota, Hawkins, Philip, Hegenbart, Ute, Palladini, Giovanni, Wechalekar, Ashutosh, Schönland, Stefan O., Försti, Asta, Houlston, Richard, and Hemminki, Kari

Published
2021
Full Text
View/download PDF

29. Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation

Author

Korell, Felix, Schreck, Nicholas, Müller-Tidow, Carsten, Dreger, Peter, Luft, Thomas, Liebregts, Tobias, and Schönland, Stefan

Subjects
Stem cells -- Transplantation, Infection, Health care industry
Abstract

Author(s): Felix Korell [sup.1], Nicholas Schreck [sup.2], Carsten Müller-Tidow [sup.1], Peter Dreger [sup.1], Thomas Luft [sup.1], Tobias Liebregts, Stefan Schönland, Ute Hegenbart, Aleksandar Radujkovic, Michael Schmitt, Axel Benner Author Affiliations: [...]

Published
2022
Full Text
View/download PDF

32. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

Author

Gagelmann, Nico, Eikema, Diderik-Jan, de Wreede, Liesbeth C., Rambaldi, Alessandro, Iacobelli, Simona, Koster, Linda, Caillot, Denis, Blaise, Didier, Remémyi, Péter, Bulabois, Claude-Eric, Passweg, Jakob, Leleu, Xavier, Zver, Samo, Kobbe, Guido, Ljungman, Per, Chevallier, Patrice, Ringhoffer, Mark, Martin, Murray, Salmenniemi, Urpu, Poiré, Xavier, Lenhoff, Stig, Pioltelli, Pietro, Mordini, Nicola, Delforge, Michel, Garderet, Laurent, Schönland, Stefan, Yakoub-Agha, Ibrahim, and Kröger, Nicolaus

Published
2021
Full Text
View/download PDF

33. Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.

Author

Schreiner, Sarah, Berghaus, Natalie, Poos, Alexandra M., Raab, Marc S., Besemer, Britta, Fenk, Roland, Goldschmidt, Hartmut, Mai, Elias K., Müller-Tidow, Carsten, Weinhold, Niels, Hegenbart, Ute, Huhn, Stefanie, and Schönland, Stefan O.

Subjects
MULTIPLE myeloma, IMMUNOGLOBULIN light chains, AMYLOIDOSIS, RNA sequencing, MULTIPLE comparisons (Statistics)
Abstract

AL amyloidosis (AL) results from the misfolding of immunoglobulin light chains (IG LCs). Aim of this study was to comprehensively analyse kappa LC sequences from AL patients in comparison with multiple myeloma (MM). We analysed IGKV/IGKJ usage and associated organ tropism and IGKV1/D-33 in terms of mutational analysis and theoretical biochemical properties. cDNA and bulk RNA sequencing of the LCs of AL and MM patients. We studied 41 AL and 83 MM patients showing that IGKV1 was most expressed among kappa AL and MM, with higher frequency in AL (80% vs. 53%, p =.002). IGKV3 was underrepresented in AL (10% vs. 30%, p =.014). IGKJ2 was more commonly used in AL than in MM (39% vs. 29%). Patients with IGKV1/D-33 were associated with heart involvement (75%, p =.024). IGKV1/D-33-segments of AL had a higher mutation count (AL = 12.0 vs. MM = 10.0). FR3 and CDR3 were most frequently mutated in both, with a median mutation count in FR3 being the highest (AL = 4.0; MM = 3.5) and one mutation hotspot (FR3 (83I)) for IGKV1/D-33/IGKJ2 was associated with cardiac involvement. This study confirmed that germline usage has an influence on AL amyloidosis risk and organ involvement. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis.

Author

aus dem Siepen, Fabian, Hein, Selina, Hofmann, Eva, Nagel, Christian, Schwarting, Stéphanie K., Hegenbart, Ute, Schönland, Stefan O., Weiler, Markus, Frey, Norbert, and Kristen, Arnt V.

Subjects
CARDIAC amyloidosis, HEART failure patients, CARDIAC patients, PROGNOSIS, CARDIOVASCULAR agents, CORONARY artery disease
Abstract

Introduction: Cardiac transthyretin amyloidosis (ATTR) is a progressive, fatal disease leading to heart failure due to accumulation of amyloid fibrils in the interstitial space and may occur as a hereditary (ATTRv) or wild-type (ATTRwt) form. Guidelines recommend the use of ACE inhibitors (ACEis) and beta-blockers (BBs) as heart failure therapy (HFT) in all patients with symptomatic heart failure and reduced ejection fraction, independent of the underlying etiology. However, the prognostic benefit of ACEis and BBs in ATTR has not been elucidated in detail yet. We thus sought to retrospectively investigate the outcome of patients with ATTRwt or ATTRv under HFT. Methods: Medical records of 403 patients with cardiac ATTR (ATTRwt: n = 268, ATTRv: n = 135) were screened for long-term medication as well as clinical, laboratory, electrocardiographic and echocardiographic data. Patients were assessed between 2005 and 2020 at the University Hospital Heidelberg. Kaplan–Meier analysis was used to analyze potential differences in survival among different subgroups. Results: The mean follow-up was 28 months. In total, 43 patients (32%) with ATTRv and 140 patients (52%) with ATTRwt received HFT. Survival was significantly shorter in patients receiving HFT in ATTRv (46 vs. 83 months, p = 0.0007) vs. non-HFT. A significantly better survival was observed in patients with comorbidities (coronary artery disease, arterial hypertension) and HFT among ATTRwt patients (p = 0.004). No significant differences in survival were observed in the other subgroups. Conclusions: Survival analysis revealed a potential benefit of HFT in patients with ATTRwt and cardiac comorbidities such as coronary artery disease and/or arterial hypertension. In contrast, HFT should be used with caution in patients with ATTRv. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Gagelmann, Nico, Eikema, Diderik-Jan, Koster, Linda, Caillot, Denis, Pioltelli, Pietro, Lleonart, Juan Bargay, Reményi, Péter, Blaise, Didier, Schaap, Nicolaas, Trneny, Marek, Passweg, Jakob, Porras, Rocio Parody, Cahn, Jean Yves, Musso, Maurizio, Poiré, Xavier, Fenk, Roland, Itälä-Remes, Maija, Pavone, Vincenzo, Fouillard, Loic, Maertens, Johan, Bron, Dominique, Pouli, Anastasia, Schroyens, Wilfried, Schönland, Stefan, Garderet, Laurent, Yakoub-Agha, Ibrahim, and Kröger, Nicolaus

Published
2019
Full Text
View/download PDF

40. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance

Author

Chattopadhyay, Subhayan, Thomsen, Hauke, Weinhold, Niels, Meziane, Iman, Huhn, Stefanie, da Silva Filho, Miguel Inacio, Vodicka, Pavel, Vodickova, Ludmila, Hoffmann, Per, Nöthen, Markus M., Jöckel, Karl-Heinz, Schmidt, Börge, Landi, Stefano, Hajek, Roman, Hallmans, Göran, Pettersson-Kymmer, Ulrika, Ohlsson, Claes, Milani, Paolo, Merlini, Giampaolo, Rowcieno, Dorota, Hawkins, Philip, Hegenbart, Ute, Palladini, Giovanni, Wechalekar, Ashutosh, Schönland, Stefan O., Houlston, Richard, Goldschmidt, Hartmut, Hemminki, Kari, and Försti, Asta

Published
2020
Full Text
View/download PDF

44. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Garderet, Laurent, Iacobelli, Simona, Koster, Linda, Goldschmidt, Hartmut, Johansson, Jan-Erik, Bourhis, Jean Henri, Krejci, Marta, Leleu, Xavier, Potter, Michael, Blaise, Didier, Koenecke, Christian, Peschel, Christian, Radocha, Jakub, Metzner, Bernd, Lenain, Pascal, Schäfer-Eckart, Kerstin, Pohlreich, David, Grasso, Mariella, Caillot, Denis, Einsele, Herman, Ladetto, Marco, Schönland, Stefan, and Kröger, Nicolaus

Published
2018
Full Text
View/download PDF

46. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

Author

Sahebi, Firoozeh, Iacobelli, Simona, Sbianchi, Giulia, Koster, Linda, Blaise, Didier, Reményi, Péter, Russell, Nigel H., Ljungman, Per, Kobbe, Guido, Apperley, Jane, Trneny, Marek, Krejci, Marta, Wiktor-Jedrzejczak, Wieslaw, Sanchez, James F., Schaap, Nicolaas, Isaksson, Cecilia, Lenhoff, Stig, Browne, Paul, Scheid, Christof, Wilson, Keith M.O., Yakoub-Agha, Ibrahim, Muñiz, Soledad González, Schönland, Stefan, Morris, Curly, Garderet, Laurent, and Kröger, Nicolaus

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results